Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs

Core Insights - Johnson & Johnson (JNJ) is recognized as one of the 14 Best Dividend Growth Stocks to buy and hold in 2026 [1] - Barclays has raised its price target for JNJ from $197 to $217, citing strong sales from key drugs like Darzalex, Tremfya, and Simponi, which may exceed Q4 consensus estimates [2] - The company has invested $10.4 billion in research and development (R&D) through Q3, positioning itself as a leading innovator globally, while also maintaining strong free cash flow [3] Financial Performance - JNJ's R&D investment of $10.4 billion supports its ongoing revenue and earnings growth, allowing for continued dividend increases, currently yielding approximately 2.5% [3] - The recent acquisition of Halda Therapeutics for $3.1 billion is expected to enhance JNJ's capabilities in cancer treatment [3] Oncology Sector - Oncology is a significant area for JNJ, with key products like Rybrevant and Lazcluze targeting advanced non-small cell lung cancer, and Inlexzo expected to contribute to the oncology portfolio [4]